|Molar Mass||1257.31 g·mol−1|
|IUPAC Name||(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid|
ARA-290 Vials represent a cutting-edge research product designed exclusively for scientific investigations. Strictly intended for research purposes, these vials contain ARA-290, a promising peptide with potential applications in various fields of medical research.
ARA-290 is a synthetic peptide derived from erythropoietin (EPO), a hormone known for its role in regulating red blood cell production. ARA-290 exhibits unique anti-inflammatory and tissue-protective properties, making it a focal point in diverse research studies.
ARA-290 Vials are versatile tools for investigating a range of medical conditions and biological processes. Researchers can explore its effects on chronic diseases, tissue repair mechanisms, and autoimmune disorders.
ARA-290 and Chronic Diabetes
One notable research application of ARA-290 involves its potential impact on chronic diabetes. Studies have suggested that ARA-290 may modulate inflammatory responses associated with diabetes, offering a potential avenue for therapeutic interventions.
ARA-290 and Tissue Repair
ARA-290 has demonstrated promising results in promoting tissue repair. Research studies indicate its ability to enhance tissue regeneration and reduce inflammation, potentially contributing to novel approaches in the field of regenerative medicine.
ARA-290 and Autoimmune Disorders
Researchers are exploring the potential of ARA-290 in addressing autoimmune disorders. Preliminary studies suggest that ARA-290 may modulate immune responses, presenting possibilities for future investigations into autoimmune conditions.
ARA-290 Vials offer a valuable tool for researchers delving into the intricate realms of chronic diseases, tissue repair, and autoimmune disorders. With its unique characteristics, ARA-290 holds promise for advancing our understanding of these complex biological processes.
- Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Yamin M, Brines M. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol. 2011 Dec;232(2):126-35. doi: 10.1016/j.expneurol.2011.05.025. Epub 2011 Aug 18. PMID: 21872588; PMCID: PMC3202026. [Read More]
- Huang B, Jiang J, Luo B, Zhu W, Liu Y, Wang Z, Zhang Z. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus. J Cell Mol Med. 2018 Jul;22(7):3330-3339. doi: 10.1111/jcmm.13608. Epub 2018 Mar 23. PMID: 29570934; PMCID: PMC6010693.[Read More]
- Nairz, M., Haschka, D., Dichtl, S. et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep 7, 13012 (2017). [Read More]